Abstract
Elevated blood levels of C-reactive protein (CRP) have been linked to colorectal cancer (CRC) survival. We evaluated genetic variants associated with CRP levels and their interactions with sex and lifestyle factors in association with CRC-specific mortality. Our study included 16 142 CRC cases from the International Survival Analysis in Colorectal Cancer Consortium. We identified 618 common single nucleotide polymorphisms (SNPs) associated with CRP levels from the NHGRI-EBI GWAS Catalog. Cox proportional hazards regression was used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for associations between SNPs and CRC-specific mortality adjusting for age, sex, genotyping platform/study and principal components. We investigated their interactions with sex and lifestyle factors using likelihood ratio tests. Of 5472 (33.9%) deaths accrued over up to 10 years of follow-up, 3547 (64.8%) were due to CRC. No variants were associated with CRC-specific mortality after multiple comparison correction. We observed strong evidence of interaction between variant rs1933736 at FRK gene and sex in relation to CRC-specific mortality (corrected Pinteraction =.0004); women had higher CRC-specific mortality associated with the minor allele (HR = 1.11, 95% CI = 1.04-1.19) whereas an inverse association was observed for men (HR = 0.88, 95% CI = 0.82-0.94). There was no evidence of interactions between CRP-associated SNPs and alcohol, obesity or smoking. Our study observed a significant interaction between sex and a CRP-associated variant in relation to CRC-specific mortality. Future replication of this association and functional annotation of the variant are needed.
Original language | English (US) |
---|---|
Pages (from-to) | 1447-1454 |
Number of pages | 8 |
Journal | International Journal of Cancer |
Volume | 150 |
Issue number | 9 |
DOIs | |
State | Published - May 1 2022 |
Keywords
- C-reactive protein
- colorectal cancer
- genetic variants
- survival
ASJC Scopus subject areas
- Oncology
- Cancer Research
Access to Document
Other files and links
Fingerprint
Dive into the research topics of 'Genetic variants associated with circulating C-reactive protein levels and colorectal cancer survival: Sex-specific and lifestyle factors specific associations'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Genetic variants associated with circulating C-reactive protein levels and colorectal cancer survival : Sex-specific and lifestyle factors specific associations. / Huang, Yuhan; Hua, Xinwei; Labadie, Julia D. et al.
In: International Journal of Cancer, Vol. 150, No. 9, 01.05.2022, p. 1447-1454.Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - Genetic variants associated with circulating C-reactive protein levels and colorectal cancer survival
T2 - Sex-specific and lifestyle factors specific associations
AU - Huang, Yuhan
AU - Hua, Xinwei
AU - Labadie, Julia D.
AU - Harrison, Tabitha A.
AU - Dai, James Y.
AU - Lindstrom, Sara
AU - Lin, Yi
AU - Berndt, Sonja I.
AU - Buchanan, Daniel D.
AU - Campbell, Peter T.
AU - Casey, Graham
AU - Gallinger, Steven J.
AU - Gunter, Marc J.
AU - Hoffmeister, Michael
AU - Jenkins, Mark A.
AU - Sakoda, Lori C.
AU - Schoen, Robert E.
AU - Diergaarde, Brenda
AU - Slattery, Martha L.
AU - White, Emily
AU - Giles, Graham
AU - Brenner, Hermann
AU - Chang-Claude, Jenny
AU - Joshi, Amit
AU - Ma, Wenjie
AU - Pai, Rish K.
AU - Chan, Andrew T.
AU - Peters, Ulrike
AU - Newcomb, Polly A.
N1 - Funding Information: Australian NHMRC Grants, Grant/Award Numbers: 509348, 209057, 251553, 504711; Canadian Institutes of Health Research, Grant/Award Number: 112746; Cancer Research UK Manchester Centre, Grant/Award Numbers: 14136 to EPIC‐Norfolk, C8221/A29017 to EPIC‐Oxford; German Research Council, Grant/Award Numbers: BR 1704/6‐1, BR 1704/6‐3, BR 1704/6‐4, CH 117/1‐1, HO 5117/2‐1, HE 5998/2‐1, KL 2354/3‐1, RO 2270/8‐1, BR 1704/17‐1; Medical Research Council, Grant/Award Numbers: 1000143 to EPIC‐Norfolk, MR/M012190/1 to EPIC‐Oxford; National Cancer Institute (NCI), National Institutes of Health (NIH), Grant/Award Numbers: U01 CA167551, U01/U24 CA074794, R01 CA076366; National Cancer Institute, National Institutes of Health, U.S. Department of Health and Human Services, Grant/Award Number: R01 CA176272; National Heart, Lung, and Blood Institute, National Institutes of Health, U.S. Department of Health and Human Services, Grant/Award Numbers: HHSN268201100046C, HHSN268201100001C, HHSN268201100002C, HHSN268201100003C, HHSN268201100004C, HHSN271201100004C; National Institutes of Health, Grant/Award Numbers: K05 CA154337, P01 CA055075, UM1 CA167552, U01 CA167552, R01 CA13, R01 CA048998, R01 CA137178, P01 CA087969, UM1 CA186107, R01 CA15, U01 CA122839, R01 CA143247, U19 CA148107, R01 CA81488, R01 CA151993, R35 CA197735, R01 CA042182; National Institutes of Health (NIH), Genes, Environment and Health Initiative (GEI), Grant/Award Numbers: Z01 CP 010200, NIH U01 HG004446, NIH GEI U01 H; NCI, EDRN Grant, Grant/Award Number: U01 CA 084968‐06; NIH/NCI Cancer Center Support Grant, Grant/Award Number: P30 CA015704; Ontario Research Fund, Grant/Award Number: GL201‐043; ORIP Grant, Grant/Award Number: S10OD028685; The German Federal Ministry of Education and Research, Grant/Award Numbers: 01KH0404, 01ER0814, 01ER0815, 01ER1505A, 01ER15; The Johns Hopkins University, Grant/Award Number: HHSN268201200008I; UK Biobank Resource, Grant/Award Number: 8614; Swedish Cancer Society, Swedish Research Council and County Councils of Skåne and Västerbotten (Sweden); Health Research Fund (FIS)—Instituto de Salud Carlos III (ISCIII), Regional Governments of Andalucía, Asturias, Basque Country, Murcia and Navarra and the Catalan Institute of Oncology—ICO (Spain); Dutch Ministry of Public Health, Welfare and Sports (VWS), Netherlands Cancer Registry (NKR), LK Research Funds, Dutch Prevention Funds, Dutch ZON (Zorg Onderzoek Nederland), World Cancer Research Fund (WCRF), Statistics Netherlands (The Netherlands); Associazione Italiana per la Ricerca sul Cancro‐AIRC‐Italy, Compagnia di SanPaolo and National Research Council (Italy); German Cancer Aid, German Cancer Research Center (DKFZ), German Institute of Human Nutrition Potsdam‐Rehbruecke (DIfE), Federal Ministry of Education and Research (BMBF) (Germany); Ligue Contre le Cancer, Institut Gustave Roussy, Mutuelle Générale de l'Education Nationale, Institut National de la Santé et de la Recherche Médicale (INSERM) (France); Danish Cancer Society (Denmark); NIHR Imperial Biomedical Research Centre (BRC); Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London; International Agency for Research on Cancer (IARC) Funding information Funding Information: CPS‐II: The authors thank the CPS‐II participants and Study Management Group for their invaluable contributions to this research. The authors would also like to acknowledge the contribution to our study from central cancer registries supported through the Centers for Disease Control and Prevention National Program of Cancer Registries and cancer registries supported by the National Cancer Institute Surveillance Epidemiology and End Results program. Funding Information: Funding information: ISACC: National Cancer Institute, National Institutes of Health, U.S. Department of Health and Human Services (R01 CA176272). This research was funded in part through the NIH/NCI Cancer Center Support Grant P30 CA015704. Scientific Computing Infrastructure at Fred Hutch funded by ORIP grant S10OD028685. The Colon Cancer Family Registry (CCFR, www.coloncfr.org ) is supported in part by funding from the National Cancer Institute (NCI), National Institutes of Health (NIH) (award U01 CA167551). Support for case ascertainment was provided in part from the Surveillance, Epidemiology and End Results (SEER) Program and the following US state cancer registries: AZ, CO, MN, NC, NH; and by the Victoria Cancer Registry (Australia) and Ontario Cancer Registry (Canada). The CCFR Set‐1 (Illumina 1M/1M‐Duo) and Set‐2 (Illumina Omni1‐Quad) scans were supported by NIH awards U01 CA122839 and R01 CA143247 (to GC). The CCFR Set‐3 (Affymetrix Axiom CORECT Set array) was supported by NIH award U19 CA148107 and R01 CA81488 (to SBG). The CCFR Set‐4 (Illumina OncoArray 600K SNP array) was supported by NIH award U19 CA148107 (to SBG) and by the Center for Inherited Disease Research (CIDR), which is funded by the NIH to the Johns Hopkins University, contract number HHSN268201200008I. Additional funding for the OFCCR/ARCTIC was through award GL201‐043 from the Ontario Research Fund (to BWZ), award 112746 from the Canadian Institutes of Health Research (to TJH), through a Cancer Risk Evaluation (CaRE) Program grant from the Canadian Cancer Society (to SG) and through generous support from the Ontario Ministry of Research and Innovation. The SFCCR Illumina HumanCytoSNP array was supported in part through NCI/NIH awards U01/U24 CA074794 and R01 CA076366 (to PAN). The content of this article does not necessarily reflect the views or policies of the NCI, NIH or any of the collaborating centers in the Colon Cancer Family Registry (CCFR), nor does mention of trade names, commercial products or organizations imply endorsement by the US Government, any cancer registry or the CCFR. CPS‐II: The American Cancer Society funds the creation, maintenance and updating of the Cancer Prevention Study‐II (CPS‐II) cohort. Our study was conducted with Institutional Review Board approval. DACHS: This work was supported by the German Research Council (BR 1704/6‐1, BR 1704/6‐3, BR 1704/6‐4, CH 117/1‐1, HO 5117/2‐1, HE 5998/2‐1, KL 2354/3‐1, RO 2270/8‐1 and BR 1704/17‐1), the Interdisciplinary Research Program of the National Center for Tumor Diseases (NCT), Germany and the German Federal Ministry of Education and Research (01KH0404, 01ER0814, 01ER0815, 01ER1505A and 01ER1505B). DALS: National Institutes of Health (R01 CA048998 to M. L. Slattery). EDRN: This work is funded and supported by the NCI, EDRN Grant (U01 CA 084968‐06). EPIC: The coordination of EPIC is financially supported by International Agency for Research on Cancer (IARC) and also by the Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London which has additional infrastructure support provided by the NIHR Imperial Biomedical Research Centre (BRC). The national cohorts are supported by: Danish Cancer Society (Denmark); Ligue Contre le Cancer, Institut Gustave Roussy, Mutuelle Générale de l'Education Nationale, Institut National de la Santé et de la Recherche Médicale (INSERM) (France); German Cancer Aid, German Cancer Research Center (DKFZ), German Institute of Human Nutrition Potsdam‐Rehbruecke (DIfE), Federal Ministry of Education and Research (BMBF) (Germany); Associazione Italiana per la Ricerca sul Cancro‐AIRC‐Italy, Compagnia di SanPaolo and National Research Council (Italy); Dutch Ministry of Public Health, Welfare and Sports (VWS), Netherlands Cancer Registry (NKR), LK Research Funds, Dutch Prevention Funds, Dutch ZON (Zorg Onderzoek Nederland), World Cancer Research Fund (WCRF), Statistics Netherlands (The Netherlands); Health Research Fund (FIS)—Instituto de Salud Carlos III (ISCIII), Regional Governments of Andalucía, Asturias, Basque Country, Murcia and Navarra and the Catalan Institute of Oncology—ICO (Spain); Swedish Cancer Society, Swedish Research Council and County Councils of Skåne and Västerbotten (Sweden); Cancer Research UK (14136 to EPIC‐Norfolk; C8221/A29017 to EPIC‐Oxford), Medical Research Council (1000143 to EPIC‐Norfolk; MR/M012190/1 to EPIC‐Oxford) (United Kingdom). Harvard cohorts (HPFS, NHS, PHS): HPFS is supported by the National Institutes of Health (P01 CA055075, UM1 CA167552, U01 CA167552, R01 CA137178, R01 CA151993 and R35 CA197735), NHS by the National Institutes of Health (R01 CA137178, P01 CA087969, UM1 CA186107, R01 CA151993 and R35 CA197735) and PHS by the National Institutes of Health (R01 CA042182). MCCS cohort recruitment was funded by VicHealth and Cancer Council Victoria. The MCCS was further supported by Australian NHMRC grants 509348, 209057, 251553 and 504711 and by infrastructure provided by Cancer Council Victoria. Cases and their vital status were ascertained through the Victorian Cancer Registry (VCR) and the Australian Institute of Health and Welfare (AIHW), including the National Death Index and the Australian Cancer Database. PLCO: Intramural Research Program of the Division of Cancer Epidemiology and Genetics and supported by contracts from the Division of Cancer Prevention, National Cancer Institute, NIH, DHHS. Funding was provided by National Institutes of Health (NIH), Genes, Environment and Health Initiative (GEI) Z01 CP 010200, NIH U01 HG004446 and NIH GEI U01 HG 004438. UK Biobank: This research has been conducted using the UK Biobank Resource under Application Number 8614. VITAL: National Institutes of Health (K05 CA154337). WHI: The WHI program is funded by the National Heart, Lung and Blood Institute, National Institutes of Health, U.S. Department of Health and Human Services through contracts HHSN268201100046C, HHSN268201100001C, HHSN268201100002C, HHSN268201100003C, HHSN268201100004C and HHSN271201100004C. Funding Information: EPIC: Where authors are identified as personnel of the International Agency for Research on Cancer/World Health Organization, the authors alone are responsible for the views expressed in this article and they do not necessarily represent the decisions, policy or views of the International Agency for Research on Cancer/World Health Organization. Harvard cohorts (HPFS, NHS, PHS): The study protocol was approved by the institutional review boards of the Brigham and Women's Hospital and Harvard T.H. Chan School of Public Health and those of participating registries as required. We would like to thank the participants and staff of the HPFS, NHS and PHS for their valuable contributions as well as the following state cancer registries for their help: AL, AZ, AR, CA, CO, CT, DE, FL, GA, ID, IL, IN, IA, KY, LA, ME, MD, MA, MI, NE, NH, NJ, NY, NC, ND, OH, OK, OR, PA, RI, SC, TN, TX, VA, WA, WY. The authors assume full responsibility for analyses and interpretation of these data. PLCO: The authors thank the PLCO Cancer Screening Trial screening center investigators and the staff from Information Management Services Inc and Westat Inc. Most importantly, we thank the study participants for their contributions that made our study possible. Cancer incidence data have been provided by the District of Columbia Cancer Registry, Georgia Cancer Registry, Hawaii Cancer Registry, Minnesota Cancer Surveillance System, Missouri Cancer Registry, Nevada Central Cancer Registry, Pennsylvania Cancer Registry, Texas Cancer Registry, Virginia Cancer Registry and Wisconsin Cancer Reporting System. All are supported in part by funds from the Center for Disease Control and Prevention, National Program for Central Registries, local states or by the National Cancer Institute, Surveillance, Epidemiology and End Results program. The results reported here and the conclusions derived are the sole responsibility of the authors. SFCCR: The authors would like to thank the study participants and staff of the Seattle Colon Cancer Family Registry and the Hormones and Colon Cancer study (CORE Studies). WHI: The authors thank the WHI investigators and staff for their dedication and the study participants for making the program possible. A full listing of WHI investigators can be found at: http://www.whi.org/researchers/Documents%20%20Write%20a%20Paper/WHI%20Investigator%20Short%20List.pdf . Publisher Copyright: © 2021 UICC.
PY - 2022/5/1
Y1 - 2022/5/1
N2 - Elevated blood levels of C-reactive protein (CRP) have been linked to colorectal cancer (CRC) survival. We evaluated genetic variants associated with CRP levels and their interactions with sex and lifestyle factors in association with CRC-specific mortality. Our study included 16 142 CRC cases from the International Survival Analysis in Colorectal Cancer Consortium. We identified 618 common single nucleotide polymorphisms (SNPs) associated with CRP levels from the NHGRI-EBI GWAS Catalog. Cox proportional hazards regression was used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for associations between SNPs and CRC-specific mortality adjusting for age, sex, genotyping platform/study and principal components. We investigated their interactions with sex and lifestyle factors using likelihood ratio tests. Of 5472 (33.9%) deaths accrued over up to 10 years of follow-up, 3547 (64.8%) were due to CRC. No variants were associated with CRC-specific mortality after multiple comparison correction. We observed strong evidence of interaction between variant rs1933736 at FRK gene and sex in relation to CRC-specific mortality (corrected Pinteraction =.0004); women had higher CRC-specific mortality associated with the minor allele (HR = 1.11, 95% CI = 1.04-1.19) whereas an inverse association was observed for men (HR = 0.88, 95% CI = 0.82-0.94). There was no evidence of interactions between CRP-associated SNPs and alcohol, obesity or smoking. Our study observed a significant interaction between sex and a CRP-associated variant in relation to CRC-specific mortality. Future replication of this association and functional annotation of the variant are needed.
AB - Elevated blood levels of C-reactive protein (CRP) have been linked to colorectal cancer (CRC) survival. We evaluated genetic variants associated with CRP levels and their interactions with sex and lifestyle factors in association with CRC-specific mortality. Our study included 16 142 CRC cases from the International Survival Analysis in Colorectal Cancer Consortium. We identified 618 common single nucleotide polymorphisms (SNPs) associated with CRP levels from the NHGRI-EBI GWAS Catalog. Cox proportional hazards regression was used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for associations between SNPs and CRC-specific mortality adjusting for age, sex, genotyping platform/study and principal components. We investigated their interactions with sex and lifestyle factors using likelihood ratio tests. Of 5472 (33.9%) deaths accrued over up to 10 years of follow-up, 3547 (64.8%) were due to CRC. No variants were associated with CRC-specific mortality after multiple comparison correction. We observed strong evidence of interaction between variant rs1933736 at FRK gene and sex in relation to CRC-specific mortality (corrected Pinteraction =.0004); women had higher CRC-specific mortality associated with the minor allele (HR = 1.11, 95% CI = 1.04-1.19) whereas an inverse association was observed for men (HR = 0.88, 95% CI = 0.82-0.94). There was no evidence of interactions between CRP-associated SNPs and alcohol, obesity or smoking. Our study observed a significant interaction between sex and a CRP-associated variant in relation to CRC-specific mortality. Future replication of this association and functional annotation of the variant are needed.
KW - C-reactive protein
KW - colorectal cancer
KW - genetic variants
KW - survival
UR - http://www.scopus.com/inward/record.url?scp=85122885405&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85122885405&partnerID=8YFLogxK
U2 - 10.1002/ijc.33897
DO - 10.1002/ijc.33897
M3 - Article
C2 - 34888857
AN - SCOPUS:85122885405
SN - 0020-7136
VL - 150
SP - 1447
EP - 1454
JO - International Journal of Cancer
JF - International Journal of Cancer
IS - 9
ER -